Hogan et al. conducted a case-series study aimed to investigate whether the improvements in psoriasis severity seen with GLP-1 analog therapy, specifically liraglutide, were linked to direct effects on invariant natural killer T (iNKT) cells. The gene discussed is GLP1R; the disease is psoriasis.